Immunosuppressants - Fiji | Statista Market Forecast

In Fiji, the revenue in the Immunosuppressants market is estimated to reach US$597.70k in 2024.
It is anticipated that the revenue will exhibit a compound annual growth rate (CAGR 2024-2029) of 15.18%, leading to a market volume of US$1.21m by 2029.
When compared globally, United States is expected to generate the highest revenue in this market, with US$35.47bn in 2024.
Fiji has seen a rise in demand for immunosuppressants as the country's healthcare system works to manage autoimmune diseases and organ transplants.

Definition:
The Immunosuppressants market covers drugs which suppress the immune response. These remedies are used in different therapy areas, mainly to treat auto-immune diseases, such as psoriasis. Anti-rejection drugs administered after organ transplantations are also included in this market. Monoclonal antibodies are an important type of immunosuppressant.

Additional information:
Market values represent the revenues generated by manufacture prices paid to primary vendors, either directly or through distribution channels (excluding VAT). Reported market revenues include spending by consumers (B2C), companies (B2B), and governments (B2G).

Company examples: Johnson & Johnson, Sanofi, Novartis

Drugs to suppress the immune response
Immunosuppressants to treat auto-immune diseases, such as psoriasis
Anti-rejection drugs

Multiple sclerosis drugs
Anti-rheumatic drugs
Immuno-oncology drugs
Antivirals
Antibiotics
Corticosteroids
HIV drugs

The Immunosuppressants market in Fiji has been experiencing steady growth in recent years, driven by increasing demand for organ transplants and rising prevalence of autoimmune diseases.

Customer preferences: Patients in Fiji prefer branded immunosuppressants due to their perceived higher quality and efficacy. However, the high cost of branded drugs has led to a growing demand for generic alternatives. Patients also prefer oral formulations over injectables, as they are more convenient and less painful.

Trends in the market: The Immunosuppressants market in Fiji is expected to continue growing due to the rising incidence of autoimmune diseases such as lupus and rheumatoid arthritis. The market is also being driven by an increasing number of kidney and liver transplants being performed in the country. Additionally, the government's efforts to improve healthcare infrastructure and increase access to healthcare services are expected to further boost the demand for immunosuppressants.

Local special circumstances: The high cost of immunosuppressants is a major challenge in Fiji, as many patients cannot afford the medication. This has led to a growing demand for government subsidies and increased access to affordable generic drugs. Additionally, the lack of trained healthcare professionals and limited healthcare infrastructure in rural areas has resulted in uneven access to immunosuppressants across the country.

Underlying macroeconomic factors: Fiji's economy has been growing steadily in recent years, driven by tourism, construction, and manufacturing sectors. The country's growing middle class and increasing healthcare spending are expected to further boost the demand for immunosuppressants. However, the country's reliance on imports for most pharmaceutical products, including immunosuppressants, makes the market vulnerable to external factors such as currency fluctuations and supply chain disruptions.

Data coverage:

Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.

Modeling approach / Market size:

Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.

Forecasts:

In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.

Additional notes:

Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.

This report presents a comprehensive analysis and additional information on the Health market, in a PDF format.

The global pharmaceutical industry has experienced significant growth during the past two decades, with revenues totaling around 1.6 trillion U.S. dollars in 2023. With growth like that, the industry's size is now comparable to the gross domestic products (GDPs) of countries like Spain, Mexico, or Australia.